Skip to main content
SHIELD THERAPEUTICS PLC logo

SHIELD THERAPEUTICS PLC — Investor Relations & Filings

Ticker · STX ISIN · GB00BYV81293 LEI · 213800G74QWY15FC3W71 IL Manufacturing
Open in API
Filings indexed 408 across all filing types
Latest filing 2018-04-11 Earnings Release
Country GB United Kingdom
Listing IL STX

About SHIELD THERAPEUTICS PLC

https://www.shieldtherapeutics.com/

Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency. The company's mission is to improve the lives of patients suffering from this condition, with or without anemia. Its lead product is Accrufer® (ferric maltol), also marketed as Feraccru®, a novel, stable, non-salt-based oral therapy. This innovative pharmaceutical is broadly indicated for use in adults across multiple therapeutic categories, aiming to provide an effective and well-tolerated treatment for a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Preliminary Results for the Year Ended 31 Dec 17
Earnings Release Classification · 95% confidence The document is titled 'Preliminary Results for the Year Ended 31 December 2017' and contains key financial highlights, revenue figures, net loss, and operational updates. It is an initial announcement of financial results, which fits the definition of an Earnings Release (ER). While it contains significant detail, it is structured as a press release (RNS) announcing the preliminary results rather than the full audited Annual Report (10-K). FY 2017
2018-04-11 English
Appointment of Non-Executive Director
Board/Management Information Classification · 98% confidence The document is a formal announcement dated April 6, 2018, originating from Shield Therapeutics plc, identified by the RNS Number '0741K'. The core content announces the 'Appointment of Non-Executive Director' and provides required regulatory disclosures regarding the new director's background and previous directorships, specifically mentioning compliance with 'Schedule Two paragraph (g) of the AIM Rules for Companies'. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of Board/Management Information (MANG). Although it is distributed via RNS, the specific subject matter is MANG, which takes precedence over the general regulatory filing category.
2018-04-06 English
Results of Pre-Submission Meeting with FDA
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and the date, indicating it is a regulatory announcement. The content details the results of a pre-submission meeting with the FDA regarding a New Drug Application (NDA) for Feraccru®, an update on strategic review (licensing options), and the appointment of a Non-Executive Director. It also mentions an upcoming preliminary results announcement and hosts a conference call. This type of broad, material corporate update, which is disseminated via the RNS system, fits best under the general 'Regulatory Filings' category, as it is not a specific financial report (10-K, IR, ER, MRQ) nor a specific management/governance document (MANG, DEF 14A). Since it is a formal announcement disseminated through the regulatory news service (RNS), and it covers multiple material business updates, RNS is the most appropriate classification, acting as the general regulatory announcement fallback.
2018-04-06 English
Broadening of Feraccru indication
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and the date, indicating it is a regulatory announcement disseminated via the London Stock Exchange's RNS service. The content announces a significant corporate event: the European Commission's approval broadening the indication for the drug Feraccru®. This is a material, non-financial operational update concerning regulatory achievement and market expansion. It is not a full financial report (10-K, IR), a management discussion (MDA), or a standard earnings release (ER). Since it is a specific, material announcement disseminated through the regulatory news service (RNS), and it doesn't fit the specific categories like DIRS, DIV, or MANG, the most appropriate classification is the general regulatory announcement category, RNS, as per the definitions provided.
2018-03-27 English
Update on the AEGIS-CKD study
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and the company name, indicating it is a regulatory announcement disseminated via the Regulatory News Service (RNS). The content discusses an 'Update on the AEGIS-CKD study' and details interactions with the FDA regarding data analysis for a pre-NDA meeting. This is a specific operational/clinical update concerning drug development and regulatory submissions, not a comprehensive annual report (10-K), a formal earnings release (ER), or a general shareholder vote result (DVA). Since it is a specific, material announcement released through the official regulatory channel (RNS), and it doesn't fit neatly into the other specific categories like M&A (TAR) or Director's Dealing (DIRS), the most appropriate classification is the general Regulatory Filings category (RNS), as it is explicitly flagged as an RNS release.
2018-03-16 English
Receives CHMP positive opinion on Feraccru®
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and the date, indicating it is a regulatory announcement disseminated via the Regulatory News Service (RNS). The content discusses a significant corporate event: Shield Therapeutics receiving a positive opinion from the CHMP for its drug Feraccru®. This is a material announcement concerning regulatory progress and potential market expansion, which is typical for a regulatory filing. Since it is an announcement of a regulatory/scientific development rather than a full financial report (like 10-K or IR) or a transcript, the most appropriate classification is RNS, which serves as the general regulatory announcement category.
2018-02-23 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.